Stem definition | Drug id | CAS RN |
---|---|---|
358 | 674-38-4 |
Dose | Unit | Route |
---|---|---|
45 | mg | O |
Property | Value | Reference |
---|---|---|
MRTD (Maximum Recommended Therapeutic Daily Dose) | 14.53 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
S (Water solubility) | 625.41 mg/mL | Bocci G, Oprea TI, Benet LZ |
Date | Agency | Company | Orphan |
---|---|---|---|
Oct. 12, 1948 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Peritonitis | 36.12 | 23.89 | 13 | 1119 | 17141 | 63470749 |
Fall | 25.49 | 23.89 | 33 | 1099 | 392301 | 63095589 |
Hypertensive nephropathy | 25.34 | 23.89 | 5 | 1127 | 647 | 63487243 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Potentiating drug interaction | 76.18 | 27.02 | 18 | 670 | 4959 | 34951284 |
Oesophageal rupture | 60.62 | 27.02 | 10 | 678 | 429 | 34955814 |
Urinary tract infection | 42.21 | 27.02 | 24 | 664 | 84057 | 34872186 |
Pancreatic failure | 29.72 | 27.02 | 6 | 682 | 792 | 34955451 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Potentiating drug interaction | 64.73 | 21.63 | 18 | 1650 | 8801 | 79733919 |
Oesophageal rupture | 52.38 | 21.63 | 10 | 1658 | 929 | 79741791 |
Urinary tract infection | 30.67 | 21.63 | 33 | 1635 | 274479 | 79468241 |
Peritonitis | 27.92 | 21.63 | 13 | 1655 | 28023 | 79714697 |
Infective pulmonary exacerbation of cystic fibrosis | 26.46 | 21.63 | 10 | 1658 | 12841 | 79729879 |
Pancreatic failure | 25.07 | 21.63 | 6 | 1662 | 1622 | 79741098 |
Hypertensive nephropathy | 22.34 | 21.63 | 5 | 1663 | 1009 | 79741711 |
None
Source | Code | Description |
---|---|---|
ATC | N07AB02 | NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS PARASYMPATHOMIMETICS Choline esters |
FDA MoA | N0000000104 | Cholinergic Muscarinic Agonists |
CHEBI has role | CHEBI:38325 | muscarinic agonists |
FDA EPC | N0000175840 | Cholinergic Muscarinic Agonist |
MeSH PA | D018678 | Cholinergic Agents |
MeSH PA | D018679 | Cholinergic Agonists |
MeSH PA | D018721 | Muscarinic Agonists |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D010277 | Parasympathomimetics |
MeSH PA | D018373 | Peripheral Nervous System Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Retention of urine | indication | 267064002 | |
Urinary tract obstruction | contraindication | 7163005 | DOID:5200 |
Irritable bowel syndrome | contraindication | 10743008 | DOID:9778 |
Peptic ulcer | contraindication | 13200003 | DOID:750 |
Increased gastric tonus | contraindication | 18644006 | |
Inflammatory bowel disease | contraindication | 24526004 | DOID:0050589 |
Orthostatic hypotension | contraindication | 28651003 | |
Parkinsonism | contraindication | 32798002 | |
Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Low blood pressure | contraindication | 45007003 | |
Peritonitis | contraindication | 48661000 | |
Bradycardia | contraindication | 48867003 | |
Parkinson's disease | contraindication | 49049000 | DOID:14330 |
Abnormal vasomotor function | contraindication | 70670009 | |
Epilepsy | contraindication | 84757009 | DOID:1826 |
Gastrointestinal obstruction | contraindication | 126765001 | |
Asthma | contraindication | 195967001 | DOID:2841 |
Atrioventricular block | contraindication | 233917008 | DOID:0050820 |
Anastomosis of intestine | contraindication | 235407009 | |
Bladder outflow obstruction | contraindication | 236645006 | |
Operation on gastrointestinal tract | contraindication | 386621005 | |
Disorder of coronary artery | contraindication | 414024009 | |
Bladder Surgery | contraindication |
None
None
None
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Muscarinic acetylcholine receptor M2 | GPCR | AGONIST | Ki | 4 | IUPHAR | CHEMBL | |||
Muscarinic acetylcholine receptor M3 | GPCR | AGONIST | Ki | 4.20 | IUPHAR | CHEMBL | |||
Muscarinic acetylcholine receptor M1 | GPCR | AGONIST | Ki | 4 | IUPHAR | ||||
Muscarinic acetylcholine receptor M4 | GPCR | AGONIST | Ki | 4 | IUPHAR | ||||
Muscarinic acetylcholine receptor | GPCR | Kd | 4.90 | CHEMBL | |||||
Muscarinic receptor 2 | GPCR | EC50 | 6 | CHEMBL |
ID | Source |
---|---|
4019634 | VUID |
N0000147727 | NUI |
D01000 | KEGG_DRUG |
590-63-6 | SECONDARY_CAS_RN |
19257 | RXNORM |
C0053526 | UMLSCUI |
CHEBI:3084 | CHEBI |
CHEMBL1482 | ChEMBL_ID |
DB01019 | DRUGBANK_ID |
CHEMBL1768 | ChEMBL_ID |
D018723 | MESH_DESCRIPTOR_UI |
2370 | PUBCHEM_CID |
297 | IUPHAR_LIGAND_ID |
004F72P8F4 | UNII |
3310 | MMSL |
4281 | MMSL |
d01427 | MMSL |
31178001 | SNOMEDCT_US |
31690003 | SNOMEDCT_US |
372698003 | SNOMEDCT_US |
4017938 | VANDF |
4019634 | VANDF |
001691 | NDDF |
004683 | NDDF |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1329 | TABLET | 50 mg | ORAL | ANDA | 17 sections |
Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1329 | TABLET | 50 mg | ORAL | ANDA | 17 sections |
Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1332 | TABLET | 5 mg | ORAL | ANDA | 17 sections |
Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1332 | TABLET | 5 mg | ORAL | ANDA | 17 sections |
Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1340 | TABLET | 10 mg | ORAL | ANDA | 17 sections |
Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1340 | TABLET | 10 mg | ORAL | ANDA | 17 sections |
Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1356 | TABLET | 25 mg | ORAL | ANDA | 17 sections |
Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1356 | TABLET | 25 mg | ORAL | ANDA | 17 sections |
Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-0510 | TABLET | 5 mg | ORAL | ANDA | 19 sections |
Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-0510 | TABLET | 5 mg | ORAL | ANDA | 19 sections |
Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-0511 | TABLET | 10 mg | ORAL | ANDA | 19 sections |
Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-0511 | TABLET | 10 mg | ORAL | ANDA | 19 sections |
Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-0512 | TABLET | 25 mg | ORAL | ANDA | 19 sections |
Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-0512 | TABLET | 25 mg | ORAL | ANDA | 19 sections |
Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-0513 | TABLET | 50 mg | ORAL | ANDA | 19 sections |
Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-0513 | TABLET | 50 mg | ORAL | ANDA | 19 sections |
Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6178 | TABLET | 25 mg | ORAL | ANDA | 10 sections |
Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6178 | TABLET | 25 mg | ORAL | ANDA | 10 sections |
Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-516 | TABLET | 10 mg | ORAL | ANDA | 18 sections |
Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-517 | TABLET | 25 mg | ORAL | ANDA | 18 sections |
Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-518 | TABLET | 50 mg | ORAL | ANDA | 18 sections |
Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50111-323 | TABLET | 5 mg | ORAL | ANDA | 19 sections |
Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50111-324 | TABLET | 10 mg | ORAL | ANDA | 19 sections |
Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50111-325 | TABLET | 25 mg | ORAL | ANDA | 19 sections |
Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50111-326 | TABLET | 50 mg | ORAL | ANDA | 19 sections |
Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51293-645 | TABLET | 5 mg | ORAL | ANDA | 10 sections |
Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51293-646 | TABLET | 10 mg | ORAL | ANDA | 10 sections |
Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51293-647 | TABLET | 25 mg | ORAL | ANDA | 10 sections |
Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51293-648 | TABLET | 50 mg | ORAL | ANDA | 10 sections |
Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53746-571 | TABLET | 5 mg | ORAL | ANDA | 10 sections |